The terms, per the grant. On April 30, 2024, Translate Bio was issued US11969480B2, covering processes of preparing mRNA-loaded lipid nanoparticles. The CPC tags — A61K 48/0091 (gene-therapy preparation), A61K 9/5123 (lipid particles), plus the B01F mixing-apparatus series — describe the manufacturing operations that load mRNA into the delivery particle.
Why process IP anchors supply deals: the bottleneck in scaling mRNA medicine is reproducible, high-quality manufacturing. IP covering the mixing and loading processes is exactly what a manufacturing or supply collaboration is written around, because it determines yield, consistency, and cost-of-goods.
The structure point: a process-IP deal supports supply agreements, contract-manufacturing arrangements, and process licenses rather than drug royalties. The value scales with manufacturing volume across partners and is partly insulated from any single product's clinical fate. For a model, that is an infrastructure-grade royalty stream.
What the grant does not promise: a clinical result or an approval — it is a manufacturing method. It is an exclusivity claim on a way of making the product, valuable to the extent partners need that process.
The takeaway: when an mRNA supply or manufacturing deal crosses the desk, the process grants are the load-bearing assets. Translate Bio's April 2024 LNP-process grant is a dated example of the manufacturing IP behind that deal layer.